Skip to Main Content

First cancer. Now, Parkinson’s?

The idea that one disease is actually several, each driven by its own genetics and differing in everything from age of onset to response to drugs, made cancer the poster child for precision medicine. Now, a $4 million study announced on Monday aims to see whether a genetically informed precision-medicine approach might work for Parkinson’s, too.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.